Home / Intelligence /

Search

Webinars

Market Access Opportunities & Challenges: An Exploration of Three Global Trends

Available On Demand

Join Trinity Life Sciences’ Evidence, Value, Access and Pricing and Cell & Gene Therapy experts for a deeper look at the market access trends that will present the most impactful opportunities and challenges for life sciences organizations in 2023.This webinar will expand upon the trends discussed in the recently released white paper entitled “Global Market Access Trends: 2022 Edition,” focusing on evolving evidence expectations, increasing price transparency regulation and cell & gene therapy expansion. Key Webinar Topics How can life…

Watch Now

Webinars

Enabling Contracting Capabilities: Uncovering the What, When and How

Available On Demand

Is your company planning to begin commercial contracting or preparing to contract within a new channel? If you are a leader in a pre-commercial or commercial emerging life sciences company facing these challenges, this webinar is designed for you. Join our experts from TGaS Advisors, a division of Trinity Life Sciences, as we share what you need to know whether you are embarking on your commercial contracting journey or thinking about a new contracting channel such as payer contracting, provider…

Watch Now

White Papers

Global Market Access Trends: 2022 Edition

Trinity Life Sciences’ Evidence, Value, Access and Pricing experts identify the key global market access trends that will enable life sciences executives to identify opportunities, combat challenges and ultimately secure success in 2023.  Download this white paper to understand:  The five key market access trends emanating from 2022 that foretell the opportunities and challenges that lie ahead in 2023 (and beyond).  In-depth insights from 11 U.S. and 24 ex-U.S. payers from Trinity Life Sciences’ ‘Global Market Access Payer Survey’.  How…

Read Now

Webinars

Business Development: Getting Pricing & Access Inputs Right

Available On Demand

Trinity invites life sciences executives to join us for a dynamic discussion on the most common high-impact challenges inherent in Business Development: What contributes to inaccurate pricing and market access assumptions in the quick-paced Business Development process? How do you de-risk pricing and access at each stage of the diligence process? Chad Faulkner, Partner in Trinity’s Strategic Advisory practice, will host this session and moderate a panel with special guests Monica Martin De Bustamante—Senior Partner & Head of Evidence, Value,…

Watch Now

Webinars

IRA Medicare Inflation Penalties: Implications for Manufacturer Pricing and Contract Strategy Decision Making

Available On Demand

What do ‘pricing inflation penalties’ actually mean for manufacturers of biopharma products? Explore the impact of the Inflation Reduction Act (IRA) on biopharmaceutical product net prices and contract strategies as manufacturers adapt to new U.S. market conditions. In this webinar, Trinity Life Sciences’ Evidence, Value, Access & Pricing practice experts will provide a high-level review of IRA policy updates before exploring the implications for currently marketed Medicare Part B and Part D therapies, as well as for future product launches.…

Watch Now

Webinars

What’s Keeping Payers Up at Night?

Available On Demand

The U.S. market access landscape is becoming increasingly competitive and complex. It is now more important than ever for drug manufacturers to keep abreast of what payers are thinking to maximize the likelihood of receiving favorable reimbursement outcomes. Through in-depth and ongoing conversations with Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs), Trinity’s Value, Access and Pricing experts uncover what payers believe to be the most critical factors shaping pricing and market access decision-making for manufacturers over the next…

Watch Now

Blog

Inflation Reduction Act of 2022: No Room for Negotiation

Published August 12, 2022

Long-awaited Medicare price negotiations look more like statutory discounts than the value-based negotiations seen in global healthcare systems; combined with expanded price increase rebates and out of pocket limits, new regulation may drive prices for new drugs up more than down. Trinity explores the impact and implications for manufacturers of innovative medicines.  Headline Summary: After over a year of drafting, Congress recently passed the Inflation Reduction Act, and on August 16th President Biden formally signed the act into law The…

Read Now

Blog

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

Published July 20, 2022

Summary Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers In contrast, biosimilar versions of adalimumab have been available in most countries outside the U.S. since 2018, resulting in high pricing disparities between immunology and inflammatory treatments between the U.S. and other markets Trinity’s Take Adalimumab biosimilar competition in Europe, as well as policy and payer pressure, has exerted downward pricing pressure for…

Read Now

Case Studies

Early P&MA Forecasting Support for a Pipeline Asset

Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research. Geographic Scope: Client Situation The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization. Trinity’s Solution Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting…

Read Now

Blog

CMS Hospital Pricing Transparency: One Price Fits All?

Published August 2, 2021

Executive Summary: A CMS regulation from the Trump Administration requiring hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021 but is still widely ignored by hospitals A lack of enforcement coupled with minor penalties decreases the efficacy of the requirement, resulting in low incentive for hospitals to comply with the rule The data posted by compliant hospitals shows large variation in pricing for…

Read Now